Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Structure Therapeutics (GPCR) Non-cash Items (2022 - 2025)

Quarterly Non-cash Items rose 50.12% to $75.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.5 million through Dec 2025, up 50.12% year-over-year, with the annual reading at $75.5 million for FY2025, 1032.27% up from the prior year.

Structure Therapeutics' Non-cash Items history spans 4 years, with the latest figure at $75.5 million for Q4 2025.

  • Non-cash Items came in at $75.5 million for Q4 2025, up from $50.3 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $158.9 million in Q3 2023 to a low of $13.3 million in Q4 2022.
  • The 4-year median for Non-cash Items is $83.3 million (2024), against an average of $85.6 million.
  • Year-over-year, Non-cash Items soared 781.53% in 2023 and then plummeted 65.76% in 2024.
  • Structure Therapeutics' Non-cash Items stood at $13.3 million in 2022, then surged by 781.53% to $117.1 million in 2023, then plummeted by 57.05% to $50.3 million in 2024, then soared by 50.12% to $75.5 million in 2025.
  • Per Business Quant, the three most recent readings for GPCR's Non-cash Items are $75.5 million (Q4 2025), $50.3 million (Q4 2024), and $54.4 million (Q3 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Structure Therapeutics 8.43 Bn 8.43 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 75.50 Mn
Dec 31, 2025 75.50 Mn
Dec 31, 2024 50.29 Mn
Dec 31, 2024 50.29 Mn
Sep 30, 2024 54.40 Mn
Sep 30, 2024 54.40 Mn
Jun 30, 2024 91.10 Mn
Jun 30, 2024 91.10 Mn
Mar 31, 2024 109.57 Mn
Mar 31, 2024 109.57 Mn
Dec 31, 2023 117.09 Mn
Dec 31, 2023 117.09 Mn
Sep 30, 2023 158.86 Mn
Sep 30, 2023 158.86 Mn
Jun 30, 2023 127.87 Mn
Jun 30, 2023 127.87 Mn
Mar 31, 2023 58.07 Mn
Mar 31, 2023 58.07 Mn
Dec 31, 2022 13.28 Mn
Dec 31, 2022 13.28 Mn